Background Pyoderma gangrenosum (PG) in inflammatory bowel disease (IBD) is
uncommon and therapeutically challenging. Its treatment remains poorly characterised due …

Pyoderma gangrenosum (PG) is a rare ulcerative skin disease that presents a therapeutic
challenge. Tumour necrosis factor alpha (TNFα) inhibitors have been reported to …

Pyoderma gangrenosum (PG) is an uncommon inflammatory skin disorder characterized by
neutrophil dysfunction. There are currently no FDA-approved drugs for the treatment of this …

The histopathologic features of PG are nonspecific and vary depending on the clinical
variant, stage of the lesion, and area of the lesion from which the skin biopsy is taken. A …

Background Over the past few decades, advances in medical research and diagnostic tools
have shed light on some aspects of pyoderma gangrenosum (PG). Nevertheless, the …

A 25-year-old woman who had been diagnosed 9 years ago with ulcerative colitis
(UC)(pancolitis) was referred to our gastroenterology department with a necrotic, painful skin …

In recent years, the therapeutic armamentarium available to dermatologists has been
extended thanks to the development of numerous biologic agents. In our field …

We read with interest the letter by De la Morena et al1 on the efficacy of infliximab in the
treatment of a case of refractory and infected pyoderma gangrenosum (PG) associated with …

Pyoderma Gangrenosum Associated With Inflammatory Bowel Disease. Report of Two Cases
With Good Response to Infliximab - ScienceDirect Skip to main contentSkip to article Elsevier …

Delayed diagnosis of pyoderma gangrenosum: a case study. - Abstract - Europe PMC Sign in
| Create an account https://orcid.org Europe PMC Menu About Tools Developers Help Contact …